You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ZANTAC 75 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Zantac 75, and when can generic versions of Zantac 75 launch?

Zantac 75 is a drug marketed by Chattem Sanofi and is included in two NDAs.

The generic ingredient in ZANTAC 75 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac 75

A generic version of ZANTAC 75 was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZANTAC 75?
  • What are the global sales for ZANTAC 75?
  • What is Average Wholesale Price for ZANTAC 75?
Summary for ZANTAC 75
US Patents:0
Applicants:1
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 117
Clinical Trials: 22
Patent Applications: 2,243
What excipients (inactive ingredients) are in ZANTAC 75?ZANTAC 75 excipients list
DailyMed Link:ZANTAC 75 at DailyMed
Drug patent expirations by year for ZANTAC 75
Recent Clinical Trials for ZANTAC 75

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Spaulding Clinical Research LLCPhase 1
Food and Drug Administration (FDA)Phase 1
Nova Scotia Health AuthorityPhase 4

See all ZANTAC 75 clinical trials

US Patents and Regulatory Information for ZANTAC 75

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chattem Sanofi ZANTAC 75 ranitidine hydrochloride TABLET, EFFERVESCENT;ORAL 020745-001 Feb 26, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZANTAC 75

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chattem Sanofi ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.